Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Understanding the targets and mechanisms of human immunity to malaria caused by
Plasmodium falciparum is crucial for advancing effective vaccines and develo** tools for …

Cerebral malaria is the most deadly manifestation of infection with Plasmodium falciparum.
The pathology of cerebral malaria is characterized by the accumulation of infected …

After a successful invasion, malaria parasite Plasmodium falciparum extensively remodels
the infected erythrocyte cellular architecture, conferring cytoadhesive properties to the …

Coevolution of humans and malaria parasites has generated an intricate balance between
the immune system of the host and virulence factors of the parasite, equilibrating maximal …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …

Numerous efforts to understand the functional roles of antibodies demonstrated that they can
protect against malaria. However, it is unclear which antibody responses are the best …

There have been significant decreases in malaria mortality and morbidity in the last 10-15
years, and the most advanced pre-erythrocytic malaria vaccine, RTS, S, received a positive …

Protective immunity to malaria depends on acquisition of parasite-specific antibodies, with
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) being one of the most …

Sequence diversity in pathogen antigens is an obstacle to the development of interventions
against many infectious diseases. In malaria caused by Plasmodium falciparum, the PfEMP1 …